Decoupling the roles
of the farnesoid X nuclear receptor and Takeda
G-protein-coupled bile acid receptor 5 is essential for the development
of novel bile acid therapeutics targeting metabolic and neurodegenerative
diseases. Herein, we describe the synthesis of 12β-methyl-18-nor-bile acids which may serve as probes in the search for
new bile acid analogues with clinical applicability. A Nametkin-type
rearrangement was applied to protected cholic acid derivatives, giving
rise to tetra-substituted Δ13,14- and Δ13,17-unsaturated 12β-methyl-18-nor-bile
acid intermediates (24a and 25a). Subsequent
catalytic hydrogenation and deprotection yielded 12β-methyl-18-nor-chenodeoxycholic acid (27a) and its 17-epi-epimer (28a) as the two major reaction
products. Optimization of the synthetic sequence enabled a chromatography-free
route to prepare these bile acids at a multi-gram scale. In addition,
the first cis-C-D ring-junctured bile acid and a
new 14(13 → 12)-abeo-bile acid are described.
Furthermore, deuteration experiments were performed to provide mechanistic
insights into the formation of the formal anti-hydrogenation product
12β-methyl-18-nor-chenodeoxycholic acid (27a).